MLOps for Medical Devices
The set of practices and tooling for deploying, monitoring, retraining, and governing machine learning models in regulated medical device software environments.
Definition
MLOps for medical devices applies appropriate quality, risk-management, software-lifecycle, validation, monitoring, and change controls to production ML systems. Under FDA’s August 18, 2025 final PCCP guidance, the current component is the Modification Protocol, not ACP. Implement only modifications consistent with the authorized PCCP without an otherwise required new submission. FDA’s January 2025 AI lifecycle guidance is a draft, not for implementation, and must not be represented as binding. Specific tooling such as immutable registries, feature stores, and per-prediction lineage should be justified by risk and intended use rather than described as universally mandated.What this means in practice
FDA-cleared AI/ML devices that include a PCCP rely on MLOps infrastructure to make iterative updates safe and traceable. The most common gap is connecting MLOps tooling to the quality system, many ML teams have excellent versioning and monitoring but cannot demonstrate the traceability and document control regulators expect. Mature MLOps for medical devices unifies the data science workflow with the design history file rather than maintaining them as parallel universes.Examples
- Illustrative: A manufacturer uses MLOps to automatically retrain an algorithm for classifying medical images, ensuring each new model version is validated and documented according to design control procedures before deployment.
- Illustrative: Through an MLOps platform, an AI diagnostic tool continuously monitors its performance in clinical use, triggering a controlled rollback to a previous, validated model version if performance degradation crosses a safety threshold.
- Illustrative: An MLOps system provides an immutable audit trail, linking every prediction made by a surgical guidance AI to its specific model version, training data, and regulatory qualification evidence, satisfying traceability requirements.
- •Maintaining ML pipelines outside the QMS, making production changes without design control evidence creates inspection findings.
- •Monitoring model performance with engineering metrics only (accuracy drift) without patient-safety thresholds, drift alone isn't actionable.
- •Treating MLOps as a generalist DevOps task, the data lineage, model lineage, and dataset versioning requirements are materially stricter than for non-ML software.
Frequently asked questions
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsMedical device that uses artificial intelligence or machine learning to perform its intended use.
Historical FDA AI/ML change-control terminology, now reflected in the PCCP Modification Protocol.
Structured documentation describing a dataset's motivation, composition, collection process, preprocessing, uses, and maintenance, the dataset equivalent of a model card.
Guiding principles for the development of AI/ML-enabled medical devices.
More in Software & AI
· Same categoryDistinction between models whose behavior is fixed at release vs. those that continue learning.
Structured documentation of a machine learning model's intended use, performance, and limitations.
Ongoing surveillance of input data and model outputs to detect performance degradation post-deployment.
FDA mechanism to pre-authorize specific modifications to AI/ML-enabled devices.
Where this term appears across MedTech Terms.
Latest in MedTech
Sources
4 sourcesSources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.
Official-source claim check:
Controlled model versions, documented validation, monitoring, and authorized change implementation support lifecycle quality controls; no universal named MLOps toolchain or per-prediction audit schema was established.
Partial review: verified corrections are applied, but this is not a full accuracy certification. The last full review date is unchanged.
Remaining verification limits
- Original merged record reviewed in full. Illustrative examples are hypothetical, not verified case histories. Evidence supports the specific propositions below, not an assertion that every linked page verifies all merged content.
- AAMI CR34971 edition/status and detailed IEC 62304 clause interpretation were not established from original full texts. Do not treat the consensus-reference or mandatory-standard claims as verified. QMSR is effective February 2, 2026; avoid presenting superseded design-control terminology as the current regulatory text without checking incorporated ISO 13485 requirements.
- 1FD&C Act section 515C (21 U.S.C. 360e-4), PCCPsTier 2 UncheckedU.S. Codefda.gov
- 2FDA - Software as a Medical Device (SaMD)Tier 2 VerifiedFDAfda.gov
- 3FDA - AI/ML-Enabled Medical DevicesTier 2 VerifiedFDAfda.gov
- 4FDA January 2025 AI lifecycle draftTier 2 UncheckedFDAfda.gov
Inline markers like [1] jump to the matching reference above.